CT-P6 clinical trials
A product of Trastuzumab; its studies count on that page too.
How each study uses CT-P6 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 Sept 1998 · HERCEPTIN · BLA 103792 (FDA, Drugs@FDA; as Trastuzumab)
- European Union
- 28 Aug 2000 · Herceptin · EMEA/H/C/000278 (EMA; as Trastuzumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- CT-P6
- 2
Studies by the year they started
3 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Trastuzumab
Studies
Open first, then newest update. How each study uses CT-P6 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)CompletedPhase 1CelltrionNCT06687928Written as CT-P6 SCReport a problem
- Demonstrate Efficacy and Safety of Metastatic Breast CancerCompletedPhase 3CelltrionNCT01084876Written as CT-P6Report a problem
- Evaluate Safety, Efficacy and PharmacokineticsCompletedPhase 1/2CelltrionNCT01084863Written as CT-P6Report a problem